CIBC Asset Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-12,851
Closed -$158K – 1132
2023
Q3
$158K Sell
12,851
-628
-5% -$9.34K ﹤0.01% 964
2023
Q2
$217K Sell
13,479
-331
-2% -$5.46K ﹤0.01% 930
2023
Q1
$240K Sell
13,810
-1,101
-7% -$15.7K ﹤0.01% 874
2022
Q4
$138K Buy
+14,911
New +$139K ﹤0.01% 988
2022
Q1
– Sell
-9,771
Closed -$333K – 1574
2021
Q4
$333K Buy
9,771
+4,932
+102% +$193K ﹤0.01% 1012
2021
Q3
$233K Buy
+4,839
New +$224K ﹤0.01% 1226
2021
Q1
– Sell
-4,034
Closed -$217K – 1356
2020
Q4
$217K Buy
+4,034
New +$182K ﹤0.01% 1094

Other funds holding NEO

CIBC Asset Management's NEO Position: Q4 2023 in Review

CIBC Asset Management sold out of NeoGenomics (NEO) in Q4 2023, closing a stake of 12,851 shares — an estimated $158K sold.

CIBC Asset Management first reported a position in NEO in Q4 2020 and held it in 7 quarters. The position peaked at $333K in Q4 2021. 287 funds tracked by Wall St. Rank hold NEO as of Q4 2023.

  • CIBC Asset Management reported no remaining NeoGenomics position as of Q4 2023 after selling out during the quarter.
  • CIBC Asset Management sold 12,851 NeoGenomics shares in Q4 2023, an estimated $158K.
  • CIBC Asset Management first reported a position in NeoGenomics in Q4 2020 and held it in 7 quarters.
  • CIBC Asset Management's NeoGenomics position peaked at $333K in Q4 2021.
  • 287 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2023.

Based on CIBC Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.